Physician profile
Christopher E Lansdown
NPI 1043420383
$1,241.25
in general payments reported to CMS, 2019-2025
19 companies · $87.35 in 2025
The $87.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $313 · 2021: $42.87 · 2022: $14.46 · 2023: $58.02 · 2024: $130 · 2025: $87.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.67 | 2019-2024 | Xifaxan |
| Pfizer INC. | $211.83 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.72 | 2019-2020 | |
| Novo Nordisk INC | $91.47 | 2019-2025 | Wegovy |
| Abbvie INC. | $87.15 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $64.93 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $44.26 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.40 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $36.91 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.59 | 2019-2020 | |
| Astellas Pharma US INC | $23.15 | 2019 | |
| Allergan, INC. | $22.60 | 2019-2020 | |
| Amgen INC. | $19.26 | 2025 | Evenity |
| Glaxosmithkline, LLC. | $15.01 | 2024 | Trelegy Ellipta |
| Mylan Specialty L.P. | $14.08 | 2024 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12.74 | 2019 | |
| Genentech USA, INC. | $12.00 | 2019 | |
| Lilly USA, LLC | $11.50 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.98 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lansdown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.